The HELEN‐006 study reported that six cycles of nab‐paclitaxel plus TP achieved a tpCR rate of 66.3% in neoadjuvant treatment of HER2‐positive breast cancer [19]. This evidence concerns the gene ERBB2 and breast cancer.